FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) - Merck.com

IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine IDVYNSO is the first and only non-INSTI, tenofovir-free, once-daily, complete…

You will be redirected in 10 seconds.